Patient Square Capital acquires Patterson Companies, Inc. for USD 2,800,000,000 (2024)

Deal facts

Buyer: Patient Square Capital
Target: Patterson Companies, Inc.
Deal value: USD 2,800,000,000
Announced: 10 December 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

17 Apr 2025CompletedClosed
Patient Square Capital completes acquisition of Patterson Companies, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the transactions contemplated by the previously announced Agreement and Plan of Merger, dated as of December 10, 2024 (the “Merger Agreement”), by and among Patterson Companies, Inc., a Minnesota corporation (the “Company”), Paradigm Parent, LLC, a Delaware limited liability company (“Parent”), an
Source

OpinionExit Mode editorial

We see a definitive shift in the healthcare distribution landscape as Patient Square Capital completes its acquisition of Patterson Companies, Inc. for 2.8 billion USD. This transaction, announced in December 2024, marks a clear move from public markets to private ownership. The deal is structured as a going private event, with the entire consideration paid in cash. This signals a strong preference among private equity firms for established healthcare assets that can operate without the quarterly earnings pressure of a listed entity. The sheer scale of the deal, at nearly three billion dollars, underscores the confidence investors hold in the resilience of the US healthcare sector despite broader economic headwinds.

For the SME founder reading this, the mechanics of a cash-only, going-private deal offer a specific lesson on exit readiness. The buyer has chosen to remove all equity risk for the target shareholders by paying 100 per cent cash. This approach often accelerates the timeline to completion because it eliminates the need for a prospectus or the complex shareholder approvals required in a stock-swap scenario. In the US context, while a transaction of this size does not automatically trigger a CMA review, it would have required clearance from the Federal Trade Commission under Hart-Scott-Rodino rules to ensure no anti-trust issues arose. The fact that the deal is already marked as completed suggests these regulatory hurdles were navigated swiftly, likely due to the buyer's clear positioning as a financial sponsor rather than a strategic competitor seeking to consolidate market share.

The choice of a pure cash deal also removes the uncertainty of earn-outs or deferred consideration that often plagues smaller transactions. We view this as a premium being placed on certainty and speed. The seller has exited with liquidity, and the buyer gains full control to restructure operations without public scrutiny. This is a powerful model for founders who prioritise a clean break over potential future upside from a public market re-rating. The decision to go private allows the new owners to invest in long-term growth strategies that might be unpalatable to public markets.

Your immediate action this week is to audit your own capital structure and identify any change-of-control covenants in your debt agreements that could be triggered by a sale. Many founders overlook these clauses until a buyer is at the table, which can delay or derail a cash deal. Review your credit facilities now to ensure you can close a transaction with the same speed and certainty we see in this Patterson deal.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More going private deals More from Patient Square Capital All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history